Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Human Coagulation Factor IX Global Market Insights 2021, Analysis and Forecast to 2026, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.
This report describes the global market size of Human Coagulation Factor IX from 2016 to 2020 and its CAGR from 2016 to 2020, and also forecasts its market size to the end of 2026 and its CAGR from 2021 to 2026.
For the geography segment, regional supply, demand, major players, price is presented from 2016 to 2026.
This report covers the following regions:
- North America
- South America
- Asia & Pacific
- Europe
- MEA
The key countries for each region are also included such as the United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For the competitor segment, the report includes global key players of Human Coagulation Factor IX as well as some small players.
The information for each competitor includes:
- Company Profile
- Main Business Information
- SWOT Analysis
- Sales Volume, Revenue, Price and Gross Margin
- Market Share
Applications Segment:
- Hospital
- Personal Clinic
- Others
Types Segment:
- AHGB
- AHFB
- Others
Companies Covered:
- Grifols
- Biogen
- Octapharma
- Baxter
- Bayer
- CSL
- Novo Nordisk
- Greencross
- Kedrion
- BPL
- Hualan Bio
- RAAS
- Pfizer
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
5.6 Covid-19 Impact
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Human Coagulation Factor Ix Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Trading Analysis
8.1 Export of Human Coagulation Factor Ix by Region
8.2 Import of Human Coagulation Factor Ix by Region
8.3 Balance of Trade
Chapter 9 Historical and Forecast Human Coagulation Factor Ix Market in North America (2016-2026)
9.1 Human Coagulation Factor Ix Market Size
9.2 Human Coagulation Factor Ix Demand by End Use
9.3 Competition by Players/Suppliers
9.4 Type Segmentation and Price
9.5 Key Countries Analysis
9.5.1 United States
9.5.2 Canada
9.5.3 Mexico
Chapter 10 Historical and Forecast Human Coagulation Factor Ix Market in South America (2016-2026)
10.1 Human Coagulation Factor Ix Market Size
10.2 Human Coagulation Factor Ix Demand by End Use
10.3 Competition by Players/Suppliers
10.4 Type Segmentation and Price
10.5 Key Countries Analysis
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Chile
10.5.4 Peru
Chapter 11 Historical and Forecast Human Coagulation Factor Ix Market in Asia & Pacific (2016-2026)
11.1 Human Coagulation Factor Ix Market Size
11.2 Human Coagulation Factor Ix Demand by End Use
11.3 Competition by Players/Suppliers
11.4 Type Segmentation and Price
11.5 Key Countries Analysis
11.5.1 China
11.5.2 India
11.5.3 Japan
11.5.4 South Korea
11.5.5 Southest Asia
11.5.6 Australia
Chapter 12 Historical and Forecast Human Coagulation Factor Ix Market in Europe (2016-2026)
12.1 Human Coagulation Factor Ix Market Size
12.2 Human Coagulation Factor Ix Demand by End Use
12.3 Competition by Players/Suppliers
12.4 Type Segmentation and Price
12.5 Key Countries Analysis
12.5.1 Germany
12.5.2 France
12.5.3 United Kingdom
12.5.4 Italy
12.5.5 Spain
12.5.6 Belgium
12.5.7 Netherlands
12.5.8 Austria
12.5.9 Poland
12.5.10 Russia
Chapter 13 Historical and Forecast Human Coagulation Factor Ix Market in MEA (2016-2026)
13.1 Human Coagulation Factor Ix Market Size
13.2 Human Coagulation Factor Ix Demand by End Use
13.3 Competition by Players/Suppliers
13.4 Type Segmentation and Price
13.5 Key Countries Analysis
13.5.1 Egypt
13.5.2 Israel
13.5.3 South Africa
13.5.4 Gulf Cooperation Council Countries
13.5.5 Turkey
Chapter 14 Summary For Global Human Coagulation Factor Ix Market (2016-2021)
14.1 Human Coagulation Factor Ix Market Size
14.2 Human Coagulation Factor Ix Demand by End Use
14.3 Competition by Players/Suppliers
14.4 Type Segmentation and Price
Chapter 15 Global Human Coagulation Factor Ix Market Forecast (2021-2026)
15.1 Human Coagulation Factor Ix Market Size Forecast
15.2 Human Coagulation Factor Ix Demand Forecast
15.3 Competition by Players/Suppliers
15.4 Type Segmentation and Price Forecast
Chapter 16 Analysis of Global Key Vendors
16.1 Grifols
16.1.1 Company Profile
16.1.2 Main Business and Human Coagulation Factor IX Information
16.1.3 SWOT Analysis of Grifols
16.1.4 Grifols Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.2 Biogen
16.2.1 Company Profile
16.2.2 Main Business and Human Coagulation Factor IX Information
16.2.3 SWOT Analysis of Biogen
16.2.4 Biogen Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.3 Octapharma
16.3.1 Company Profile
16.3.2 Main Business and Human Coagulation Factor IX Information
16.3.3 SWOT Analysis of Octapharma
16.3.4 Octapharma Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.4 Baxter
16.4.1 Company Profile
16.4.2 Main Business and Human Coagulation Factor IX Information
16.4.3 SWOT Analysis of Baxter
16.4.4 Baxter Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.5 Bayer
16.5.1 Company Profile
16.5.2 Main Business and Human Coagulation Factor IX Information
16.5.3 SWOT Analysis of Bayer
16.5.4 Bayer Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.6 CSL
16.6.1 Company Profile
16.6.2 Main Business and Human Coagulation Factor IX Information
16.6.3 SWOT Analysis of CSL
16.6.4 CSL Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.7 Novo Nordisk
16.7.1 Company Profile
16.7.2 Main Business and Human Coagulation Factor IX Information
16.7.3 SWOT Analysis of Novo Nordisk
16.7.4 Novo Nordisk Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.8 Greencross
16.8.1 Company Profile
16.8.2 Main Business and Human Coagulation Factor IX Information
16.8.3 SWOT Analysis of Greencross
16.8.4 Greencross Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.9 Kedrion
16.9.1 Company Profile
16.9.2 Main Business and Human Coagulation Factor IX Information
16.9.3 SWOT Analysis of Kedrion
16.9.4 Kedrion Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.10 BPL
16.10.1 Company Profile
16.10.2 Main Business and Human Coagulation Factor IX Information
16.10.3 SWOT Analysis of BPL
16.10.4 BPL Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.11 Hualan Bio
16.11.1 Company Profile
16.11.2 Main Business and Human Coagulation Factor IX Information
16.11.3 SWOT Analysis of Hualan Bio
16.11.4 Hualan Bio Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.12 RAAS
16.12.1 Company Profile
16.12.2 Main Business and Human Coagulation Factor IX Information
16.12.3 SWOT Analysis of RAAS
16.12.4 RAAS Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
16.13 Pfizer
16.13.1 Company Profile
16.13.2 Main Business and Human Coagulation Factor IX Information
16.13.3 SWOT Analysis of Pfizer
16.13.4 Pfizer Human Coagulation Factor IX Sales, Revenue, Price and Gross Margin (2016-2021)
For more information about this report visit https://www.researchandmarkets.com/r/smmg0l
